.
.
.
.
Coronavirus

Health Canada follows European regulators in backing AstraZeneca’s COVID-19 vaccine

Published: Updated:

Canada’s health department on Thursday joined its European counterparts in backing AstraZeneca Plc’s COVID-19 vaccine, saying the shots were not associated with an overall increase in blood clots.

“Health Canada confirms that the benefits of the AstraZeneca COVID-19 vaccine in protecting Canadians from COVID-19 continue to outweigh the risks,” the regulator said in a statement.

For more coronavirus news, visit our dedicated page.

“To date in Canada, there has been one report of a stroke that occurred in an individual following vaccination,” the regulator said. “This case has been assessed by Health Canada and determined not to be related to the vaccine.”

Earlier, the European Union said the vaccine was “safe and effective” and British regulators said its use should continue, after reports of rare blood clots prompted over a dozen countries to suspend the use of the vaccine.

Germany, France and other European nations have since announced plans to resume using the vaccine.

For all the latest headlines follow our Google News channel online or via the app.

Health Canada also said it had assessed available data on the events and had determined the shot was not associated with an increase in the overall risk of blood clots.

The country is using AstraZeneca doses made at the Serum Institute of India. It has received 500,000 doses and expects to get 1.5 million more by May.

Read more:

EU’s drug regulator backs ‘safe and effective’ AstraZeneca vaccine

UK reports five cases of blood clotting in brain among AstraZeneca vaccine recipients

Blood clots: What they are, the symptoms, what you can do to avoid them